mammalian
proprotein
convertas
furin
found
play
import
role
divers
physiolog
patholog
event
activ
viral
glycoprotein
bacteri
exotoxin
small
nontox
highli
activ
furin
inhibitor
consid
attract
drug
candid
diseas
caus
viru
bacteria
studi
seri
peptid
inhibitor
design
synthes
base
ctermin
fragment
histon
inhibitori
effect
furin
replac
reactiv
site
inhibitor
consensu
substrat
recognit
sequenc
furin
found
increas
inhibitori
activ
greatli
potent
inhibitor
amino
acid
residu
k
valu
nm
furin
although
synthes
peptid
temporari
inhibitor
inhibitor
nine
amino
acid
retain
full
potenc
even
h
incub
period
furin
inhibitor
may
potenti
lead
develop
antivir
antibacteri
drug
compound
mammalian
proprotein
convertas
furin
found
play
import
role
divers
physiolog
patholog
event
activ
viral
glycoprotein
bacteri
exotoxin
small
nontox
highli
activ
furin
inhibitor
consid
attract
drug
candid
diseas
caus
viru
bacteria
studi
seri
peptid
inhibitor
design
synthes
base
ctermin
fragment
histon
inhibitori
effect
furin
replac
reactiv
site
inhibitor
consensu
substrat
recognit
sequenc
furin
found
increas
inhibitori
activ
greatli
potent
inhibitor
amino
acid
residu
k
valu
nm
furin
although
synthes
peptid
temporari
inhibitor
inhibitor
nine
amino
acid
retain
full
potenc
even
h
incub
period
furin
inhibitor
may
potenti
lead
develop
antivir
antibacteri
drug
compound
furin
inhibitor
histon
peptid
synthesi
secretori
pathway
proprotein
limit
cleav
famili
proteolyt
enzym
call
proprotein
convertas
pc
pc
calciumdepend
serin
proteas
whose
catalyt
domain
share
sequenc
similar
bacteri
subtilisin
cleavag
import
process
wide
use
regul
activ
peptid
protein
play
signific
role
variou
biolog
event
implic
homeostasi
variou
diseas
furin
mammalian
pc
first
identifi
extens
studi
furin
shown
effect
differ
substrat
bloodclot
factor
growth
factor
hormon
receptor
matrix
metalloproteinas
ion
channel
bacteri
exotoxin
diphtheria
toxin
anthrax
toxin
viral
envelop
glycoprotein
hiv
sar
viru
also
process
furin
furthermor
mani
studi
indic
increas
furin
activ
close
relat
malign
variou
tumor
thu
furin
attract
target
therapeut
drug
mani
furin
inhibitor
studi
includ
small
molecular
pc
inhibitor
proteinbas
inhibitor
small
molecular
pc
inhibitor
categor
peptid
inhibitor
peptidomimet
inhibitor
nonpeptid
inhibitor
proteinbas
inhibitor
includ
polypeptid
deriv
prodomain
pc
bioengin
protein
endogen
protein
among
antitrypsin
portland
polyarginin
use
prevent
activ
bacteri
toxin
process
envelop
glycoprotein
viral
replic
metastasi
cancer
comparison
small
peptid
inhibitor
attract
furin
inhibitor
sinc
potent
low
toxic
mani
peptid
inhibitor
investig
exampl
design
base
sequenc
pc
prodomain
pc
partner
protein
lysin
activ
domain
mung
bean
trypsin
inhibitor
mbti
peptid
inhibitor
includ
consensu
substrat
recognit
sequenc
furin
ctermin
modifi
activ
group
noh
meanwhil
stabil
small
peptid
inhibitor
improv
cyclic
peptid
inhibitor
chymotrypsin
inhibitor
barley
serin
proteinas
sunflow
trypsin
ly
fragment
mung
bean
trypsin
inhibitor
previou
studi
three
highli
activ
inhibitor
furin
purifi
porcin
liver
identifi
ctermin
truncat
fragment
differ
size
histon
inhibitori
activ
fragment
greater
fulllength
histon
suggest
inhibitori
activ
furin
reli
upon
ctermin
domain
studi
synthes
amino
acid
peptid
ctermin
fragment
retain
inhibitori
activ
furin
howev
amino
acid
peptid
k
valu
long
wide
applic
lack
abil
inhibit
activ
furin
effici
studi
use
small
amino
acid
peptid
templat
design
shorter
potent
stabl
furin
inhibitor
seven
peptid
inhibitor
deriv
amino
acid
peptid
synthes
potenc
stabil
furin
character
found
nonapeptid
high
stabil
k
valu
may
serv
lead
compound
develop
therapeut
drug
furinmedi
diseas
hiv
fluorogen
substrat
mca
purchas
bachem
bioscienc
san
diego
usa
fmoc
amino
acid
fmoc
resin
obtain
appli
biosystem
foster
citi
usa
linear
peptid
synthes
use
standard
fmoc
chemistri
protect
peptid
independ
grown
wangresin
use
hbtu
obenzotriazolen
n
n
ntetramethyluroniumhexafluorophosph
hobt
nhydroxybenzotriazol
amino
acid
activ
method
solid
phase
peptid
synthesi
perform
peptid
synthes
appli
biosystem
protect
amino
acid
fmocser
tbu
fmocli
tboc
fmocthr
tbu
fmocarg
pbf
fmocasp
otbu
resin
incub
tfa
contain
pcresol
drop
triethylsilan
thioanisol
h
room
temperatur
cleavag
crude
peptid
precipit
cool
anhydr
diethyl
ether
purifi
revers
phase
hplc
cyclic
peptid
synthes
correspond
linear
peptid
thioester
precursor
intramolecular
nativ
chemic
ligat
linear
peptid
thioester
precursor
prepar
use
boc
solid
phase
method
situ
neutral
typic
acid
preactiv
hbtudiea
n
ndiisopropylethylamin
introduc
leupam
resin
deprotect
neat
tfa
first
amino
acid
ctermin
coupl
resin
free
thiol
group
use
hbtudiea
coupl
reagent
chain
elong
finish
protect
group
remov
peptid
cleav
resin
hf
hydrogen
fluorid
pcresol
peptid
precipit
wash
cold
diethyl
ether
purifi
revers
phase
hplc
cycliz
linear
peptid
perform
phosphat
buffer
contain
guanidin
hydrochlorid
ph
overnight
reaction
monitor
rphplc
cyclic
product
purifi
hplc
identifi
electrospray
ionizationmass
spectrometri
synthet
peptid
desalt
sephadex
column
amersham
bioscienc
piscataway
usa
wash
buffer
tfa
water
lyophil
dissolv
buffer
purifi
zorbax
column
mm
agil
palo
alto
usa
hplc
peptid
equilibr
buffer
flow
rate
mlmin
elut
gradient
buffer
b
tfa
acetonitril
min
buffer
b
min
molecular
mass
synthet
peptid
determin
abi
qtrap
mass
spectroscop
appli
biosystem
fluorogen
mca
substrat
pyrargthrlysargmca
use
furin
activ
assay
determin
inhibitori
activ
differ
amount
inhibitor
first
incub
fix
amount
enzym
min
final
volum
ml
hepe
buffer
mm
hepe
mm
cacl
triton
mm
residu
enzym
activ
measur
fluoresc
spectrophotomet
hitachi
tokyo
japan
stabil
assay
inhibitor
incub
furin
differ
period
min
inhibitori
activ
measur
enzym
incub
without
inhibitor
measur
control
excit
emiss
wavelength
nm
slit
width
nm
nm
slit
width
nm
respect
k
valu
inhibitor
furin
determin
dixon
plot
use
two
differ
concentr
substrat
substrat
concentr
stabil
assay
data
three
measur
averag
graphic
analyz
equat
obtain
equilibrium
inhibit
constant
k
hplc
use
studi
stabil
peptid
inhibitor
peptid
inhibitor
without
incub
furin
hepe
buffer
h
place
buffer
centrifug
supern
load
pepmap
column
mm
appli
biosystem
equilibr
buffer
flow
rate
mlmin
elut
gradient
buffer
b
min
buffer
b
min
equilibr
buffer
b
flow
rate
mlmin
elut
gradient
buffer
b
min
buffer
b
min
molecular
mass
peak
determin
abi
qtrap
mass
spectroscop
report
previou
work
peptid
bear
k
valu
amino
acid
residu
paaatvtkkvakspkkakaakpkkaaksaakavkpk
deriv
ctermin
fragment
histon
possess
potent
inhibitori
activ
furin
base
amino
acid
peptid
templat
term
seri
shorter
peptid
design
synthes
tabl
fig
first
step
optim
shorten
amino
acid
peptid
nand
ctermin
result
peptid
term
amino
acid
residu
exhibit
lower
inhibitori
activ
improv
potenc
second
step
introduc
consensu
substrat
recognit
sequenc
furin
reactiv
site
furin
recogn
specif
site
peptid
design
replac
p
residu
ly
p
p
p
residu
arg
replac
led
decreas
k
valu
approxim
suggest
consensu
substrat
sequenc
furin
essenti
inhibitor
two
alanin
residu
p
p
posit
replac
asp
p
leu
p
respect
achiev
k
valu
furin
decreas
threefold
indic
neg
charg
residu
p
site
favor
though
amino
acid
peptid
appropri
inhibitori
activ
rel
larg
size
restrain
applic
third
step
remov
ntermin
thrlyslysv
ctermin
ala
residu
flank
reactiv
site
inhibitor
obtain
truncat
termini
appar
impact
inhibitori
activ
result
nonapeptid
inhibitor
k
valu
protect
peptid
possibl
vivo
degrad
exopeptidas
three
cyclic
peptid
inhibitor
amino
acid
residu
also
synthes
thioester
format
ntermin
cystein
ctermin
leu
unexpectedli
inhibitori
potenc
peptid
decreas
fold
respect
compar
tabl
stabil
assay
carri
measur
stabil
inhibitor
sever
hour
measur
stabil
inhibitor
ic
concentr
inhibitor
use
base
k
valu
substrat
concentr
stabil
assay
enzym
incub
without
inhibitor
use
control
confirm
furin
activ
would
chang
incub
buffer
initi
inhibitori
activ
inhibitor
mark
inhibitori
activ
indic
time
point
compar
initi
activ
normal
percentag
valu
inhibitori
activ
measur
three
time
synthes
peptid
incub
furin
indic
time
inhibitori
activ
gradual
decreas
timedepend
manner
except
stabl
inhibitor
retain
potenc
furin
even
h
incub
period
contrast
inhibitor
least
stabl
activ
loss
time
period
among
inhibitor
activ
one
highest
inhibitori
activ
k
k
k
decay
fastest
five
amino
acid
longer
howev
stabl
compar
cyclic
peptid
lost
potenc
much
quickli
suggest
cycliz
peptid
help
optim
furin
inhibitor
fig
confirm
stabil
analysi
result
hplc
also
use
measur
stabil
sinc
activ
peptid
inhibitor
select
incub
furin
h
h
separ
hplc
shown
fig
h
incub
furin
right
panel
hplc
profil
incub
furin
h
left
panel
figur
insert
right
show
molecular
weight
peak
mark
measur
mass
spectrum
consist
stabil
assay
hplc
profil
show
decreas
new
peptid
gener
retent
time
min
hplc
incub
furin
h
fig
b
molecular
weight
newli
gener
peptid
kda
fig
c
good
match
calcul
molecular
weight
peptid
cleav
p
p
indic
instabl
inhibitor
caus
cleavag
furin
ctermin
p
sinc
furin
found
relat
bacteri
viral
infect
develop
atherosclerosi
alzheim
diseas
metastasi
cancer
becom
import
therapeut
target
type
diseas
furin
inhibitor
capabl
neutral
bacteri
exotoxin
prevent
viral
infect
proteinas
inhibitor
histon
report
natur
synthes
possibl
inhibitor
furin
mammal
ctermin
fragment
histon
found
potent
fulllength
histon
k
valu
nm
furin
ctermin
fragment
histon
mani
advantag
furin
inhibitor
exampl
small
size
lack
disulfid
bond
mean
easili
synthes
purifi
howev
modif
need
promot
potenc
stabil
appli
therapeut
studi
success
optim
ctermin
fragment
potent
stabl
furin
inhibitor
thu
made
attract
potenti
candid
use
therapeut
drug
crystal
structur
catalyt
domain
mous
furin
indic
activ
site
furin
form
extend
substratebind
groov
line
mani
neg
charg
residu
studi
furin
inhibitor
shown
peptid
compris
posit
charg
residu
better
furin
inhibitor
three
pocket
substrat
bind
site
furin
gener
pocket
furin
need
arg
p
site
substrateinhibitor
pocket
interact
ly
p
site
pocket
favor
interact
arg
p
site
furin
pocket
p
site
substrateinhibitor
option
thu
favor
substrat
furin
would
conserv
sequenc
furin
also
anoth
secondari
pocket
substrat
bind
site
pocket
interact
arg
site
substrateinhibitor
previou
studi
show
one
site
cleav
furin
exist
ctermin
histon
base
cleavag
site
amino
acid
design
found
potent
furin
inhibitor
k
valu
shorten
origin
peptid
amino
acid
peptid
inhibitor
design
remov
nand
ctermin
residu
flank
reactiv
site
inhibitori
activ
thu
reduc
almost
order
increas
inhibitori
potenc
design
base
optim
cleavag
site
dl
mutat
reactiv
site
markedli
increas
inhibitori
activ
indic
consensu
substrat
sequenc
furin
prefer
achiev
high
inhibitori
activ
time
substitut
asp
leu
p
p
posit
may
also
increas
inhibitori
activ
threefold
tabl
dock
nonapeptid
rerrrkkrg
furin
pocket
one
side
cyclic
peptid
studi
form
rigid
structur
amino
acid
reactiv
site
abl
bind
pocket
furin
cyclic
peptid
achiev
greater
structur
flexibl
length
circl
increas
accordingli
inhibitori
activ
increas
elong
peptid
like
peptid
inhibitor
furin
synthes
peptid
temporari
inhibitor
inhibitori
activ
gradual
decreas
timedepend
manner
notabl
lower
k
valu
quickli
activ
decay
fig
one
except
nonapeptid
k
valu
appar
chang
inhibitori
activ
found
even
h
incub
period
furin
three
cyclic
peptid
also
design
improv
inhibitor
stabil
unexpectedli
cycliz
increas
neither
potenc
stabil
inhibitor
summari
base
ctermin
fragment
histon
seri
furin
inhibitor
design
among
exhibit
highest
inhibitori
activ
stabl
inhibitor
may
serv
ideal
lead
compound
develop
therapeut
drug
use
fight
furinmedi
diseas
hiv
